Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral Vectors

被引:112
作者
Burnham, Brenda [1 ]
Nass, Shelley [1 ]
Kong, Elton [1 ]
Mattingly, MaryEllen [1 ]
Woodcock, Denise [1 ]
Song, Antonius [1 ]
Wadsworth, Samuel [1 ]
Cheng, Seng H. [1 ]
Scaria, Abraham [1 ]
O'Riordan, Catherine R. [1 ]
机构
[1] Genzyme Corp, Gene Therapy, Framingham, MA 01701 USA
关键词
LEBER CONGENITAL AMAUROSIS; GENE-THERAPY; VIRUS PRODUCTION; CELL-LINES; TRANSDUCTION; PARTICLES; SYSTEM; REP; CAP; PURIFICATION;
D O I
10.1089/hgtb.2015.048
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recombinant adeno-associated viral (rAAV) vectors represent a novel class of biopharmaceutical drugs. The production of clinical-grade rAAV vectors for gene therapy would benefit from analytical methods that are able to monitor drug product quality with regard to homogeneity, purity, and manufacturing consistency. Here, we demonstrate the novel application of analytical ultracentrifugation (AUC) to characterize the homogeneity of preparations of rAAV vectors. We show that a single sedimentation velocity run of rAAV vectors detected and quantified a number of different viral species, such as vectors harboring an intact genome, lacking a vector genome (empty particles), and containing fragmented or incomplete vector genomes. This information is obtained by direct boundary modeling of the AUC data generated from refractometric or UV detection systems using the computer program SEDFIT. Using AUC, we show that multiple parameters contributed to vector quality, including the AAV genome form (i.e., self-complementary vs. single-stranded), vector genome size, and the production and purification methods. Hence, AUC is a critical tool for identifying optimal production and purification processes and for monitoring the physical attributes of rAAV vectors to ensure their quality.
引用
收藏
页码:228 / 242
页数:15
相关论文
共 50 条
[41]   Scalable generation of high-titer recombinant adeno-associated virus type 5 in insect cells [J].
Urabe, M ;
Nakakura, T ;
Xin, KQ ;
Obara, Y ;
Mizukami, H ;
Kume, A ;
Kotin, RM ;
Ozawa, K .
JOURNAL OF VIROLOGY, 2006, 80 (04) :1874-1885
[42]   Insect cells as a factory to produce adeno-associated virus type 2 vectors [J].
Urabe, M ;
Ding, CT ;
Kotin, RM .
HUMAN GENE THERAPY, 2002, 13 (16) :1935-1943
[43]   Self-complementary recombinant adeno-associated viral vectors: Packaging capacity and the role of rep proteins in vector purity [J].
Wu, Jianqing ;
Zhao, Weihong ;
Zhong, Li ;
Han, Zongchao ;
Li, Baozheng ;
Ma, Wenqin ;
Weigel-Kelley, Kirsten A. ;
Warrington, Kenneth H., Jr. ;
Srivastava, Arun .
HUMAN GENE THERAPY, 2007, 18 (02) :171-182
[44]   Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus [J].
Xiao, X ;
Li, J ;
Samulski, RJ .
JOURNAL OF VIROLOGY, 1998, 72 (03) :2224-2232
[45]  
Yang X, 2006, J PHARM SCI, V97, P746
[46]   Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union [J].
Ylae-Herttuala, Seppo .
MOLECULAR THERAPY, 2012, 20 (10) :1831-1832
[47]   A Versatile Adeno-Associated Virus Vector Producer Cell Line Method for Scalable Vector Production of Different Serotypes [J].
Yuan, Zhenhua ;
Qiao, Chunping ;
Hu, Peiqi ;
Li, Juan ;
Xiao, Xiao .
HUMAN GENE THERAPY, 2011, 22 (05) :613-624
[48]   Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors [J].
Zeltner, N. ;
Kohlbrenner, E. ;
Clement, N. ;
Weber, T. ;
Linden, R. M. .
GENE THERAPY, 2010, 17 (07) :872-879
[49]  
Zhao H, 2013, CURR PROTOC PROTEIN
[50]  
Zhou CM, 2014, J VIROL METHODS, P191